157 related articles for article (PubMed ID: 38379420)
21. Bucillamine Prevents Afatinib-Mediated Inhibition of Epidermal Growth Factor Receptor Signaling.
Nishiya N; Murai M; Hosoda A; Yonezawa H; Omori N
Pharmaceuticals (Basel); 2019 Nov; 12(4):. PubMed ID: 31703435
[TBL] [Abstract][Full Text] [Related]
22. Skin rash caused by EGFR-TKI could be treated successfully by Pien Tze Huang Unguentum Compositum: a case report.
Zhang M; Li Q; Sun Y
J Biomed Res; 2022 Jun; 36(6):440-445. PubMed ID: 36165327
[TBL] [Abstract][Full Text] [Related]
23. Instrumental evaluation sensitively detects subclinical skin changes by the epidermal growth factor receptor inhibitors and risk factors for severe acneiform eruption.
Kikuchi K; Nozawa K; Yamazaki N; Nakai Y; Higashiyama A; Asano M; Fujiwara Y; Kanda S; Ohe Y; Takashima A; Boku N; Inoue A; Takahashi M; Mori T; Taguchi O; Inoue Y; Mizutani H
J Dermatol; 2019 Jan; 46(1):18-25. PubMed ID: 30402978
[TBL] [Abstract][Full Text] [Related]
24. Efficacy and safety of afatinib in Chinese patients with EGFR-mutated metastatic non-small-cell lung cancer (NSCLC) previously responsive to first-generation tyrosine-kinase inhibitors (TKI) and chemotherapy: comparison with historical cohort using erlotinib.
Lee VH; Leung DK; Choy TS; Lam KO; Lam PM; Leung TW; Kwong DL
BMC Cancer; 2016 Feb; 16():147. PubMed ID: 26911310
[TBL] [Abstract][Full Text] [Related]
25. Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Lu CW; Pang JS; Ko YS; Chang CJ; Wang CW; Chen WT; Chen CB; Hui RC; Hung SI; Lu LY; Lu KL; Wang CL; Wu CE; Hsu PC; Fang YF; Li SH; Ko HW; Tseng LC; Shih FY; Chen MJ; Chung WH
J Eur Acad Dermatol Venereol; 2023 Feb; 37(2):328-339. PubMed ID: 36366861
[TBL] [Abstract][Full Text] [Related]
26. Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation.
Chen PY; Wang CC; Hsu CN; Chen CY
Front Pharmacol; 2021; 12():720687. PubMed ID: 34434112
[No Abstract] [Full Text] [Related]
27. Epidermal EGFR controls cutaneous host defense and prevents inflammation.
Lichtenberger BM; Gerber PA; Holcmann M; Buhren BA; Amberg N; Smolle V; Schrumpf H; Boelke E; Ansari P; Mackenzie C; Wollenberg A; Kislat A; Fischer JW; Röck K; Harder J; Schröder JM; Homey B; Sibilia M
Sci Transl Med; 2013 Aug; 5(199):199ra111. PubMed ID: 23966300
[TBL] [Abstract][Full Text] [Related]
28. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness analysis of first and second-generation EGFR tyrosine kinase inhibitors as first line of treatment for patients with NSCLC harboring EGFR mutations.
Arrieta O; Catalán R; Guzmán-Vazquez S; Barrón F; Lara-Mejía L; Soto-Molina H; Ramos-Ramírez M; Flores-Estrada D; de la Garza J
BMC Cancer; 2020 Sep; 20(1):829. PubMed ID: 32873256
[TBL] [Abstract][Full Text] [Related]
30. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib.
Chen G; Noor A; Kronenberger P; Teugels E; Umelo IA; De Grève J
PLoS One; 2013; 8(3):e59708. PubMed ID: 23527257
[TBL] [Abstract][Full Text] [Related]
31. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
32. [Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].
Han R; Wang X; Zhong D; Zhao J; Chen Z; Sun L; Wang J; Zhang J
Zhongguo Fei Ai Za Zhi; 2012 Dec; 15(12):689-93. PubMed ID: 23249714
[TBL] [Abstract][Full Text] [Related]
33. Epithelial growth factor receptor tyrosine kinase inhibitors alleviate house dust mite allergen Der p2-induced IL-6 and IL-8.
Pan HH; Hsiao YP; Chen PJ; Kang YT; Chao YH; Sheu JN; Lue KH; Ko JL
Environ Toxicol; 2019 Apr; 34(4):476-485. PubMed ID: 30623574
[TBL] [Abstract][Full Text] [Related]
34. The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer.
Jung HA; Woo SY; Lee SH; Ahn JS; Ahn MJ; Park K; Sun JM
Transl Lung Cancer Res; 2020 Oct; 9(5):1749-1758. PubMed ID: 33209598
[TBL] [Abstract][Full Text] [Related]
35. Relationship between Biodistribution and Tracer Kinetics of
van de Stadt EA; Yaqub M; Schuit RC; Bartelink IH; Leeuwerik AF; Schwarte LA; de Langen AJ; Hendrikse H; Bahce I
Diagnostics (Basel); 2022 Apr; 12(4):. PubMed ID: 35453931
[TBL] [Abstract][Full Text] [Related]
36. Afatinib plus Cetuximab Delays Resistance Compared to Single-Agent Erlotinib or Afatinib in Mouse Models of TKI-Naïve EGFR L858R-Induced Lung Adenocarcinoma.
Pirazzoli V; Ayeni D; Meador CB; Sanganahalli BG; Hyder F; de Stanchina E; Goldberg SB; Pao W; Politi K
Clin Cancer Res; 2016 Jan; 22(2):426-35. PubMed ID: 26341921
[TBL] [Abstract][Full Text] [Related]
37. An Observational Study of Acquired
Wu SG; Chiang CL; Liu CY; Wang CC; Su PL; Hsia TC; Shih JY; Chang GC
Front Oncol; 2020; 10():1481. PubMed ID: 33014788
[TBL] [Abstract][Full Text] [Related]
38. Leukotriene B(4) enhances tumour necrosis factor-alpha-induced CCL27 production in human keratinocytes.
Kanda N; Watanabe S
Clin Exp Allergy; 2007 Jul; 37(7):1074-82. PubMed ID: 17581202
[TBL] [Abstract][Full Text] [Related]
39. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
[TBL] [Abstract][Full Text] [Related]
40. Interleukin-1β Induces Tissue Factor Expression in A549 Cells via EGFR-Dependent and -Independent Mechanisms.
Mechelke T; Wittig F; Ramer R; Hinz B
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34205482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
